Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-28

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of the study is to investigate the short-term growth in children with asthma aged 5-11 years in treatment with fluticasone propionate / formoterol spray (flutiform®) 200/20 micrograms per day

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma

NCT02502734

Asthma

COMPLETED PHASE3

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

NCT01658891

Asthma in Children

WITHDRAWN PHASE3

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

NCT01450774

Childhood Asthma

COMPLETED PHASE3

Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

NCT01332292

Asthma

COMPLETED PHASE2

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

NCT02980133

Asthma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Persistent Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Flutiform 50/5 ug (2 puffs bid) pMDI

Group Type EXPERIMENTAL

Flutiform 50/5 ug (2 puffs bid) pMDI

Intervention Type DRUG

Fluticasone 50 ug (2puffs bid) pMDI

Group Type ACTIVE_COMPARATOR

Fluticasone 50 ug (2puffs bid) pMDI

Intervention Type DRUG

Beclometasone Autohaler 50 ug (2 puffs bid)

Active control

Group Type OTHER

Beclometasone Autohaler 50 ug (2 puffs bid)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Flutiform 50/5 ug (2 puffs bid) pMDI

Intervention Type DRUG

Fluticasone 50 ug (2puffs bid) pMDI

Intervention Type DRUG

Beclometasone Autohaler 50 ug (2 puffs bid)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects to be included in the study are those who meet all of the following criteria:

1. Male and Female subjects 5 to \<12 years old. Female subjects must be pre-menarche to be eligible.
2. Subjects must be pre-adolescent without any signs of puberty (acc. to Tanner scale).
3. Subjects are in normal range for their age in height and weight. Weight and height measurements should fall within the percentile range 3-97-% of normal values for age according to Danish growth charts.
4. Known history of mild intermittent or persistent reversible asthma for ≥ 3 months prior to the screening visit.
5. Require:

1. only inhaled SABA therapy (e.g. Bricanyl Turbuhaler) on an as required basis, and/or
2. Regular non-ICS controller medications for asthma (e.g., cromones or leukotriene receptor antagonists) at a stable dose for ≥ 3 months prior to the screening visit.
6. No ICS for \>2 weeks prior to the screening visit.
7. Demonstrates adequate spirometry technique and able to use a home PEFR meter.
8. Demonstrated FEV1 of ≥ 80% predicted value at visit 1following appropriate withholding of asthma medications (if applicable) (no SABA use within 6 hours of the PFT).
9. Demonstrated satisfactory technique in the use of the pMDI plus spacer and Autohaler devices.
10. Must be continent of urine and willing to perform (with parental/guardian help) overnight urine collections.
11. Willing and able to complete morning and evening PEFR measures with the help of a parent or guardian, if necessary, and attend all study visits.
12. Willing and able to substitute pre-study prescribed inhaled asthma medication for the entire duration of the study with study medication.
13. Written informed consent obtained as per national laws.

14. FEV1 within ≤20% of the visit 1 value following appropriate withholding of rescue medication (no salbutamol Airomir Autohaler use within 6 hours of the PFT).

Exclusion Criteria

Subjects to be excluded from the study are those who meet any of the following criteria:

1. Require medications other than inhaled SABAs and/or regular non-ICS controller medications (e.g., cromones or leukotriene receptor antagonists) to maintain asthma control.
2. ICS use within ≤ 2 weeks prior to the screening visit.
3. Any asthma exacerbation of any severity for at least 3 months prior to the screening visit.
4. Any fracture in the leg to be measured by knemometry ≤6 months prior to the screening visit.
5. Any metabolic disorders or other diseases that may impact on normal growth patterns.
6. Near fatal or life-threatening asthma within the past year.
7. Hospitalisation or an emergency visit for asthma within the past 6 months.
8. History of oral or injectable corticosteroid medication ≤3 months prior to the screening visit.
9. Evidence of a clinically unstable disease, as determined by medical history, clinical laboratory tests, and physical examination that, in the Investigator's opinion, preclude entry into the study. "Clinically significant" is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study.
10. No major surgery requiring general anesthesia for at least 3 months prior to the screening visit.
11. No febrile illnesses with temperature \> 39°C within a week of the screening visit.
12. In the Investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit.
13. Significant, non-reversible active pulmonary disease (e.g. cystic fibrosis, bronchiectasis, tuberculosis).
14. Subjects who have taken β- blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrythmics, or potent CYP 3A4 inhibitors such as ketoconazole within 1 week prior to the screening visit.
15. Current use of medications, other than those allowed in the protocol.
16. Current evidence of hypersensitivity or idiosyncratic reaction to test medications or components.
17. Receipt of an Investigational medicinal product within 30 days of the screening visit.

Minimum Eligible Age

5 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No